Evidence map›Paper›PMID 34694536›Full record

ArticleBreast cancer research and treatment2022

Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN.

Ellen B Gold, Sybil L Crawford, Katherine Leung, Gail Greendale, Katherine W Reeves, Hadine Joffe, Nancy E Avis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ellen B GoldUniversity of California Davis School of Medicine, Davis, USA. ebgold@ucdavis.edu.ORCID http://orcid.org/0000-0003-1013-171X
Sybil L CrawfordUniversity of Massachusetts Medical School, Worcester, USA.ORCID http://orcid.org/0000-0001-6621-0439
Katherine LeungUniversity of Massachusetts Medical School, Worcester, USA.ORCID http://orcid.org/0000-0001-5432-923X
Gail GreendaleDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Katherine W ReevesUniversity of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, USA.ORCID http://orcid.org/0000-0001-7856-981X
Hadine JoffeHarvard Medical School, Brigham and Women's Hospital, Boston, USA.
Nancy E AvisWake Forest University School of Medicine, Winston-Salem, USA.ORCID http://orcid.org/0000-0002-1077-3037

Funding

The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old AgeU19AG063720 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Maria Mori Brooks · 2020 to 2026
$61.3M
WOMENS HEALTH ACROSS THE NATION--COORDINATING CENTERU01AG012553 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BROOKS, MARIA MORI · 1994 to 2019
$37.7M
WOMENS HEALTH ACROSS THE NATION--ENDOCRINE LABU01AG012495 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCONNELL, DANIEL S · 1994 to 2018
$18.8M
WOMENS HEALTH ACROSS THE NATION--PITTSBURGHU01AG012546 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MATTHEWS, KAREN · 1994 to 2019
$16.2M
WOMENS HEALTH ACROSS THE NATION--UCDAVISU01AG012554 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI GOLD, ELLEN B. · 1994 to 2019
$14.5M
WOMENS HEALTH ACROSS THE NATION--UCLAU01AG012539 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GREENDALE, GAIL A · 1994 to 2018
$13.7M
THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION-MICHIGANU01NR004061 · NINR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HARLOW, SIOBAN D · 1994 to 2018
$12.9M
WOMENS HEALTH ACROSS THE NATION--CHICAGOU01AG012505 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI KRAVITZ, HOWARD M · 1994 to 2019
$11.9M
WOMENS HEALTH ACROSS THE NATION--MASSACHUSETTS GENERAL HU01AG012531 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, JOEL S · 1994 to 2019
$10.7M
Women's Health Across the Nation-New Jersey SiteU01AG012535 · NIA · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI DERBY, CAROL A. · 1994 to 2019
$9.2M
Application of ambulatory methods for assessing short- and long-term associations of sleep health with cognitive decline in older adultsR01AG062622 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BUXTON, ORFEU M, DERBY, CAROL A. · 2019 to 2022
$3.1M
A Prospective Study of the Impact of Breast Cancer on Symptoms and FunctioningR01CA199137 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI AVIS, NANCY E · 2015 to 2019
$1.8M
Division of Cancer Epidemiology and Genetics, National Cancer Institute CA 199137NCI NIH HHS R01 CA199137NIA NIH HHS AG012554NIA NIH HHS R01 AG062622NIA NIH HHS U01 AG012495NIA NIH HHS U01 AG012505NIA NIH HHS U01 AG012531NIA NIH HHS U01 AG012535NIA NIH HHS U01 AG012539NIA NIH HHS U01 AG012546NIA NIH HHS U01 AG012553NIA NIH HHS U01 AG012554NIA NIH HHS U19 AG063720NINR NIH HHS U01 NR004061
6 · The paper itself

Abstract

purposeWe compared trajectories of vasomotor symptoms (VMS) and their risk factors in women with breast cancer (BrCa) to those of cancer-free controls.

methodsData were from 15 nearly annual follow-up visits (1996-2017) of the multi-racial/ethnic cohort of midlife women enrolled in the Study of Women's Health Across the Nation (SWAN). We compared women with incident BrCa to controls for patterns of VMS, controlling for risk factors identified in bivariate analyses using multivariable longitudinal analyses.

resultsCharacteristics at study entry largely did not differ between cases (n = 151) and controls (n = 2161). Adjusted prevalence of any VMS increased significantly among cases from diagnosis to 2.75 years post diagnosis [per-year adjusted odds ratio (aOR) = 1.76, 95% confidence interval (CI) 1.39-2.24], peaking at 2.75 years post diagnosis, whereas prevalence was stable among controls in this interval [aOR = 1.04, 95% CI 0.99-1.11]. Beyond 2.75 years post diagnosis, prevalence declined significantly in cases [aOR = 0.72, 95% CI 0.61-0.84] and less in controls [aOR = 0.96, 95% CI 0.92-1.00]. Patterns were similar for frequent VMS. Adjustment for tamoxifen use slightly reduced the per-year OR for any prevalent VMS post diagnosis, partially explaining excess VMS in cases. Other treatments were unassociated with VMS.

conclusionsPatterns of prevalent VMS reporting differed significantly between cases and controls, particularly post diagnosis, the latter only partially explained by tamoxifen use among cases. Risk factors for VMS largely did not differ between cases and controls.

Indexed as

Breast NeoplasmsFemaleHot FlashesHumansLongitudinal StudiesMenopauseWomen's HealthBreast cancerMenopauseRisk factorsVasomotor symptoms

Identifiers

PMID34694536
PMCPMC8758653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.